Table 3.
Description of procedure and infection site.
| Patient # | Steroid Preparation/Dosage (mg) | Technique/Level of Injection | Infection site |
|---|---|---|---|
| 1 | Methylprednisolone/80 | IL/T11-12 | Thoracic |
| 2 | Dexamethasone/16 | TF/L4-5 | Thoracic |
| 3 | Methylprednisolone/80 | TF/L5-S1 | Shoulder∗ |
| 4 | Dexamethasone/10 | TF/C5-6 | Face |
| 5 | Dexamethasone/10 | TF/S1 | Gluteal |
| 6 | Betamethasone/6 | IL/L4-5 | Gluteal |
| 7 | Dexamethasone/10 | IL/C6-7 | Vulva∗ |
| 8 | Betamethasone/6 | TF/L5 | Face∗ |
| 9 | Dexamethasone/10 | TF/L5 | Sacral |
| 10 | Betamethasone/6 | IL/L1-2 | Gluteal |
| 11 | Betamethasone/6 | IL/L4-5 | Sacral |
| 12 | Dexamethasone/10 | TF/L3-4 | Sacral |
| 13 | Dexamethasone/10 | TF/L5 | Lumbar |
| 14 | Betamethasone/6 | IL/L4-5 | Gluteal |
| 15 | Dexamethasone/10 | TF/S1 | Lumbar |
| 16 | Dexamethasone/10 | IL/L5-S1 | Cervical∗ |
| 17 | Dexamethasone/10 | TF/L4 | Thoracic |
| 18 | Dexamethasone/10 | TF/C7 | Arm |
| 19 | Betamethasone/6 | IL/L3-4 | Thoracic |
| 20 | Dexamethasone/10 | TF/C5-6 | Thoracic |
| 21 | Methylprednisolone/80 | IL/L5-S1 | Gluteal |
| 22 | Betamethasone/6 | IL/L4-5 | Cervical∗ |
| 23 | Dexamethasone/10 | IL/C6-7 | Thoracic |
| 24 | Dexamethasone/10 | TF/L5 | Thoracic |
| 25 | Dexamethasone/10 | TF/L2-3 | Face∗ |
| 26 | Methylprednisolone/80 | IL/L4-5 | Thoracic |
| 27 | Methylprednisolone/80 | IL/L4-5 | Vulva |
| 28 | Methylprednisolone/80 | IL/L5-S1 | Sacral |
| 29 | Betamethasone/12 | Caudal/Sacral hiatus | Lumbar |
| 30 | Dexamethasone/10 | TF/L5-S1 | Lumbar |
| 31 | Methylprednisolone/80 | IL/T3-4 | Face∗ |
| 32 | Dexamethasone/10 | TF/T4 | Lumbar |
| 33 | Dexamethasone/10 | TF/L3-4 | Face∗ |
| 34 | Dexamethasone/10 | Caudal/Sacral hiatus | Lumbar |
| 35 | Dexamethasone/10 | TF/L5 | Shoulder∗ |
| 36 | Betamethasone/12 | Caudal/Sacral hiatus | Lumbar |
| 37 | Dexamethasone/5 | TF/L2 | Lumbar |
IL, interlaminar; TF, transforaminal; ∗ Manifestations considered distant from the injection site.